GENEVA: Two potential vaccines against the deadly Ebola strain gripping the Democratic Republic of Congo are set to enter trials in the outbreak’s epicenter next week, the WHO announced Tuesday. There are currently no vaccines or treatments for the less common Bundibugyo species of Ebola behind the explosive outbreak declared in May, triggering an international public health emergency. A total of 5,568 deaths out of 11,376 cases have been confirmed in the vast central African country’s worst-ever Ebola outbreak, according to the World Health Organization. “We expect two candidate vaccines developed specifically for Bundibugyo virus to begin testing as early as next week,” WHO chief Tedros Adhanom Ghebreyesus told a press conference at the UN health agency’s headquarters in Geneva. The so-called Tumaini trial in the DRC is a single framework that can test the safety, efficacy and ability to trigger an immune response of multiple vaccines. The trial uses ring vaccination: immunizing contacts deemed to be at high risk of infection. Ervebo, a vaccine already approved for use against the more common Zaire strain of Ebola, kicked off the Tumaini trial on October 23, at the full-scale Phase 3 level, to determine if it also offers any protection against Bundibugyo.
The trial will now also incorporate the two Bundibugyo-specific candidate vaccines, which have both gone through earlier-stage, smaller-scale Phase…




